This trial tests a new drug to treat swelling in the back of the eye that can cause vision loss.
- Uveitic Macular Edema
1 Primary · 22 Secondary · Reporting Duration: Weeks 20 and 52
3 Treatment Groups
1 of 3
1 of 3
1 of 3
225 Total Participants · 3 Treatment Groups
Primary Treatment: Arm A · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
To what extent can Arm A pose a hazard to people?
"The risk profile of Arm A was assessed as a 3, stemming from the Phase 3 trial status and evidence-based corroboration that its efficacy is supported by sufficient data." - Anonymous Online Contributor
Does this research project presently require participants?
"Clinicaltrials.gov indicates that this investigation is actively seeking participants; the initial advertisement was published on January 13th 2023 and was last revised on January 6th 2023." - Anonymous Online Contributor
What is the cap on the number of participants in this experiment?
"Hoffmann-La Roche is overseeing the trial from Erie Retinal Surgery in Pennsylvania and Texas Retina Associates in Dallas. The experiment necessitates 225 qualified participants to commence." - Anonymous Online Contributor